Physician profile
Nadia Merchant
NPI 1245527787
$49,234.37
in general payments reported to CMS, 2019-2025
15 companies · $28K in 2025
The $28K reported for 2025 was more than what 95% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.64 · 2020: $26.04 · 2021: $4,199 · 2022: $2,431 · 2023: $8,156 · 2024: $6,086 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $5,338 · Food and Beverage: $2,378 · Honoraria: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,346.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,304.00 |
| Travel and Lodging | $5,338.18 |
| Food and Beverage | $2,377.77 |
| Honoraria | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $33,794.26 | 2021-2025 | Voxzogo 1.2mg, Palynziq, Vimizim |
| Catalyst Pharmaceuticals, INC. | $4,345.48 | 2024-2025 | |
| Novo Nordisk INC | $3,441.71 | 2020-2025 | Sogroya |
| Ascendis Pharma Endocrinology INC | $3,215.00 | 2025 | |
| Kyowa Kirin, INC. | $1,672.14 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $1,324.33 | 2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $900.00 | 2023 | Strensiq |
| Pfizer INC. | $142.65 | 2024-2025 | |
| Dexcom, INC. | $138.98 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $115.75 | 2023 | |
| Abbvie INC. | $51.05 | 2024 | |
| Beta Bionics, INC. | $32.56 | 2023-2024 | Ilet Bionic Pancreas |
| Tolmar, INC. | $28.44 | 2025 | Fensolvi |
| Tandem Diabetes Care, INC. | $20.38 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Companion Medical, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Merchant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.